基于噻吩类似物的用于光热治疗的载光敏剂脂质体的研发

Xu Yue, Li Hua, Fan Lixue, Chen Yisha, Li Li, Zhou Xiaojing, Li Ruixi, Cheng Yuru, Chen Haiyan, Yuan Zhenwei

Department of Biomedical Engineering, School of Engineering, China Pharmaceutical University, 24 Tongjia Lane, Gulou District, Nanjing 210009, China.

Georgetown University, 3700 O St NW, Washington, DC 20057, USA.

J Adv Res. 2020 Aug 6;28:165-174. doi: 10.1016/j.jare.2020.08.003. eCollection 2021 Feb.

Photothermal therapy (PTT) was considered as one of the most promising cancer therapies to overcome the severe side effects caused by chemotherapy. Hence, four thiophene analogs were developed to construct novel organic photothermal agents (PTAs) for many biomedical applications in cancer biosensing and photothermal therapies. The efficacy of four compounds was demonstrated by studies of photothermal properties as well as photothermal therapeutic effects. Besides, tumor ablation experiments indicated that HTN2 can effectively suppress tumors in vivo and in vitro as a novel PTA. Hence, PTAs that we designed and synthesized with their advantage of good biocompatibility and facile structural design could be candidates for PTT.

光热疗法（PTT）被认为是克服化疗所致严重副作用的最具前景的癌症治疗方法之一。因此，开发了四种噻吩类似物来构建新型有机光热剂（PTA），用于癌症生物传感和光热疗法中的许多生物医学应用。通过光热性质研究以及光热治疗效果证明了这四种化合物的功效。此外，肿瘤消融实验表明，HTN2作为一种新型PTA，在体内和体外均能有效抑制肿瘤。因此，我们设计合成的具有良好生物相容性和简便结构设计优势的PTA可作为光热疗法的候选物。